Surgery (RMH) - Research Publications
Now showing items 1-10 of 98
Oncogenic H-Ras Reprograms Madin-Darby Canine Kidney (MDCK) Cell-derived Exosomal Proteins Following Epithelial-Mesenchymal Transition
(AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 2013-08-27)
Epithelial-mesenchymal transition (EMT) is a highly conserved morphogenic process defined by the loss of epithelial characteristics and the acquisition of a mesenchymal phenotype. EMT is associated with increased aggressiveness, ...
Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis
Metastasis to regional lymph nodes is an important and early event in many tumors. Vascular endothelial growth factor-C (VEGF-C), VEGF-D and their receptor VEGFR-3, play a role in tumor spread via the lymphatics, although ...
Memory Impairment in Rats after Desflurane Anesthesia is Age and Dose Dependent
(IOS PRESS, 2015-01-01)
Post-operative cognitive dysfunction (POCD) predominantly affects the elderly who suffer memory and concentration deficits after anesthesia and surgery. Animal studies have demonstrated anesthetic alone may contribute to ...
Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity
(TAYLOR & FRANCIS INC, 2014-05-01)
Several agents targeting the epidermal growth factor receptor (EGFR) have been FDA-approved to treat cancer patients with varying tumor types including metastatic colorectal cancer. Many patients treated with anti-EGFR ...
Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity
(PUBLIC LIBRARY SCIENCE, 2017-02-27)
Glioblastoma (GBM) is a heterogeneous tumor of the brain with a poor prognosis due to recurrence and drug resistance following therapy. Genome-wide profiling has revealed the existence of distinct GBM molecular subtypes ...
Microfluidic single-cell transcriptional analysis rationally identifies novel surface marker profiles to enhance cell-based therapies
(NATURE PUBLISHING GROUP, 2016-06-01)
Current progenitor cell therapies have only modest efficacy, which has limited their clinical adoption. This may be the result of a cellular heterogeneity that decreases the number of functional progenitors delivered to ...
Defining the Substrate Specificity Determinants Recognized by the Active Site of C-Terminal Src Kinase-Homologous Kinase (CHK) and Identification of beta-Synuclein as a Potential CHK Physiological Substrate
(AMER CHEMICAL SOC, 2011-08-09)
C-Terminal Src kinase-homologous kinase (CHK) exerts its tumor suppressor function by phosphorylating the C-terminal regulatory tyrosine of the Src-family kinases (SFKs). The phosphorylation suppresses their activity and ...